diseas initi ow
novel cell therapi could potenti cure
wide varieti autoimmun disord initi human
data avail approach support
strong efficaci data initi diseas target
support peak sale
novel platform leverag power autoimmun diseas
cabaletta built technolog success
oncolog develop novel therapi compris engin cell
aim treat autoimmun diseas unlik target cell
indistinguish caar design kill pathogen cell potenti
avoid sever advers event deliv cur potenti multipl
autoimmun diseas believ lead program potenti support peak
sale least key safeti data efficaci data mid-
importantli cabaletta compani develop cell therapi
autoimmun diseas ip support first mover advantag
pipelin program present opportun potenti broad
applic cabaletta popul pipelin program pemphigu
vulgari pv myasthenia gravi mg hemophillia manag
identifi autoimmun diseas could appli technolog
given autoimmun diseas describ date
standard care major diseas sub-optimal see
signific potenti pipelin expans
preclin data support efficacy/safeti lead compound despit
earli stage believ cabaletta approach derisk peer
program similar stage given clinic success t-cell therapi
program manag first test technolog mucos pv
target/biolog well character preclin work pv demonstr
elimin pathogen cell effect
cell provid evid caar efficaci importantli preclin safeti data
suggest caus off-target toxic interact
human membran demonstr t-like clinic efficaci
clean safeti profil pv believ could replac rutiximab seriou
infect risk annual seriou infect risk lifetim risk fatal
 unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
infect due broad b-cell kill fda could grant acceler approv
similar kymriah earli versu base case assumpt
phi safeti toler data repres key upcom catalyst
manag commenc phi trial mucos pv announc
safety/toler data given median time onset
day see safeti data derisk caar safeti profil
expect upsid clean safeti profil without crs/neurotox
initi coverag cabaletta overweight rate price target
cabaletta clinical-stag cell therapi compani leverag technolog
develop therapi specif autoimmun diseas use construct call chimer
autoantibodi receptor manag gener support preclin data
lead compound test phi trial mucos pemphigu
vulgari pv unlik tradit therapi manag hope achiev broad
efficaci clean safeti use caar design kill diseas b-cell
compar broadli kill b-cell compon invest thesi
detail
therapi target autoimmun diseas potenti deliv efficaci
cell therapi cleaner safeti manag identifi potenti
diseas could attract candid cabaletta platform dub
exhibit build foundat cart therapi success
employ human treat cell cancer main differ epitop
surfac engin cell therapi select target kill
sole pathogen cell contrast therapi kill normal pathogen
 cell non-select select approach manag may abl deliv
therapi cur certain autoimmun diseas without signific
toxic profil icu stay day potenti death associ
exhibit overview cabaletta design platform
biolog pv well character program pv peak sale
potenti pv autoimmun blister skin diseas preval
peopl us/eu manag select mucos pv lead indic caar
technolog target well established/character includ
antibodi epitop pathogen biolog clear preclin data
support given current standard care pv lead high risk fatal
infect calcul success cabaletta product penetr
market gener risk-adjust us/eu sale exhibit provid key
info cabaletta pipelin program
exhibit potenti address market cabaletta program includ hema patient
high risk fviii neutral antibodi total hema patient assum
penetr total address popul
price
preclin data point cart-lik efficaci without toxic preclin data
suggest cell select kill pathogen cell mice effect
cell exhibit compar given cell
proven effect elimin cell human data indic potenti
deliv favor efficaci pv patient safeti front
cell establish absenc off-target toxic preclin interact
human membran neighbor human cell vitro neither kill
keratinocyt infiltr skin mice vivo exhibit collect
potenti exhibit ablat pathogen cell popul pv coupl
accept safeti profil await phi data assess translat
preclin data human
exhibit bioluminesc day cell
express igg inject caart
nontransduc cell control efficaci caart appear
equival
exhibit histolog mucos blister format acantholysi
treatment none treat mice demonstr
ellebrecht christoph et al re-engineering chimer antigen receptor cell target therapi
ellebrecht christoph et al re-engineering chimer antigen receptor cell target therapi
follow-on compound pipelin could enter clinic addit lead
program cabaletta pipelin popul three compound
target mucocutan pv muscle-specif tyrosin kinas myasthenia gravi
musk-mg hemophillia advanc compound behind
musk-caart manag gener vitro data plan present
target engag vivo data well initi ind-en studi
success musk-caart could enter clinic importantli manag
identifi autoimmun indic technolog potenti
exhibit cabaletta current pipelin beyond list program manag identifi
autoimmun indic technolog appli
upcom catalyst mucos pv program includ acut safeti data
wherea musk mg program catalyst includ confirm vivo
target engag initi ind enabl studi would expect
month efficaci data pv
acut safeti data phi trial
irb approv phi trial initi
confirm target engag initi ind enabl studi
valid manufactur support clinic program
phi primari safeti endpoint month post infus
therapi valid concept engin cell target kill cell
human readthrough clinic efficaci given similar
car/caar approach howev investor open question
uniqu aspect caar
solubl antibodi may hinder efficaci antibodi exert differ impact
function/activ base affin posit rel
refer although challeng priori assess extent solubl
antibodi impact human preclin data suggest solubl
antibodi may impact efficaci mitig risk neutral
solubl antibodi manag may pretreat patient plasmapheresi ivig
cell activ may sufficient/persist cell possess
suffici persist kill entir pathogen cell popul includ
cell escap although cell demonstr persist week
mice persist human yet establish function
similar adopt t-cell therapi major cell may disappear
circul within week prior kill pathogen cell lead
pv reappear howev believ solubl antibodi low
affin may continu trigger cell therebi contribut
persist event insuffici cell activ manag
plan increas dose
autoreact cell may escap kill although pathogen cell
escap kill cell exhibit escap cell lack surfac anti-
antibodi given cell without antibodi believ
contribut pv pathogenesi would expect escap cell
relev pv
mucos pv may driven addit antibodi beyond
propos critic combin differ autoantibodi singl
antibodi type may necessari pv pathogenesi refer addit
pv case wherein antibodi necessari
suffici caus diseas refer except rare pv case
believ vast major pv case suffici drive
diseas therefor success would target vast major pv
patient
overal target engag data inform conclus
achiev cleaner safeti profil
given seriou advers event trigger therapi oncolog
investor concern safeti profil worth note
order safeti profil accept autoimmun diseas need
favor safeti profil cancer given differ
sever unmet need two indic major attribut
treatment view includ follow
cytokin releas syndrom given relat burden
diseas exhibit believ likelihood caar-caus low
given select kill cell low compar
burden diseas therapi addit mitig risk
manag may avoid lymphodeplet use low initi dose combin
dose fraction
immun effector cellassoci neurotox syndrom ican similarli
level cart cell expans cytokin correl ican sever
thu would expect therapi trigger sever ican
activ level cell significantli lower cell
immunodefici due cell aplasia on-target off-tumor toxic given
cell select kill pathogen cell spare healthi cell
would expect immunodefici trigger cell aplasia patient treat
key catalyst around safety/toler expect
manag report acut safeti data phi trial mucos pv
replac rituximab pv
rituximab monoclon antibodi target antigen calcium
channel cell membran express cell therebi kill cell
indistinguish rituximab first drug approv fda
treatment moder sever pv
rituximab treatment effici elimin antibodi exhibit
major pv patient respons despit favor efficaci rituximab
treatment requir chronic administr weaken humor immun
system indiscrimin kill cell increas potenti
sever infect annual rituximab treatment lifetim fatal
infect risk could overcom limit requir
one-tim infus circumv need chronic administr select
target pathogen cell spare healthi cell leav immun
system intact therefor cell therapi proven deliv clinic efficaci
similar rituximab coupl accept safeti profil ultim becom
soc pv believ safeti data provid
preliminari clariti whether safeti profil could support
prefer treatment pv
broad applic
autoimmun diseas mainli driven loss b-cell toler
pathogen gener autoantibodi date distinct autoimmun diseas
describ wherein cell involv antibodi mediat well
cell mediat autoimmun diseas refer refer manag
identifi autoimmun diseas technolog could repres
signific advanc standard care therapi
given autoimmun diseas exist wherein cell possess key role believ
success technolog may potenti find broad applic
autoimmun diseas beyond three diseas current list cabaletta pipelin
exampl could also appli treat autoantibody-associ
neonat lupu syndrom refer howev think caar
technolog appli autoimmun indic autoantigen
indic meet follow criteria must interfer
physiolog function must well character
effici display cell given date limit autoantigen
identifi refer display cell may feasibl note
could limit treat known autoimmun diseas optimist
howev ultim manag could also expand applic
efficaci phase studi drive risk/reward
efficaci phase studi drive risk/reward
pt deriv discount cash flow analysi assum
discount rate termin growth valu estim us/eu
risk-adjust peak revenu use
po mucos pv/mucocutan pv/musk mg
receiv acceler fda approv
respect similar therapi kymriah estim us/eu risk-adjust
peak revenu
program approv full phiii program musk-
caart receiv tradit fda approv
respect estim us/eu risk-adjust peak revenu
fail fail receiv regulatori approv impact
overal caart platform viabil trade cash value-per-share
believ cabaletta proprietari
platform yield analog efficaci
compar therapi circumv
believ promis
compound demonstr
favor efficaci safeti profil
preclin studi see upsid
potenti acceler approv phi
believ manag continu
identifi auto-immun diseas
caart technolog appli
demonstr favor safeti profil
low rate expect
vivo target engag confirm
preclin studi musk-caart
move compound clinic test
earli
demonstr favor efficaci profil
effici specif cell targeting/kil
expect
risk achiev price
question valu
overal platform
unexpect safeti signal
caart trial would like caus investor
regul question risk-benefit ratio
lower probabl success
delay timelin posit data
present valu
discount cf
time valuat
price target includ po adjust ww revenu deriv
price target discount cash flow dcf analysi use wacc
valuat methodolog prefer use dcf analysi valu biotechnolog
compani given defin patent life product believ dcf fulli
captur up-front invest period well long-term earn power
investor look biotechnolog multipl basi price-to-earnings prefer dcf
rigor requir explicit assumpt long-term
prospect compani
discount rate util discount rate cabaletta compani
earli stage develop coverag util discount rate
commerci compani rate compani random phii data
rate develop stage compani
termin growth rate model explicit revenu assum
revenu base case scenario estim pos-adjust ww revenu
driven musk-caart current
assign valu cabaletta hemophilia asset fviii-caart given earli stage
develop posit matur data could lead us re-evaluate view
asset
econom cabaletta in-licens univers sylvania
exchang cabaletta owe low singl digit royalti
cog estim cog grow
oper expens project grow steadili
estim sg ramp
cabaletta begin gener product sale sg eventu
grow
risk price target includ clinic efficaci safeti lead
develop program remain unclear therefor risk
initi clinic readout could beli expect delay timelin may weigh
investor percept investor may write entir cabaletta platform
earli data readout meet investor expect
debat caart differenti cart
overview cabaletta leverag foundat work cell therapi
oncolog develop autoantibodi receptor cell therapi
treatment cell-medi autoimmun diseas main differ
caar cell therapi oncolog target domain
cell surfac differ allow cell select kill
pathogen cell unlik cell elimin entir cell popul
street take investor interest technolog given signific
efficaci achiev oncolog howev investor also
concern safeti commerci viabil select ablat could
impact efficaci efficaci investor encourag fact engin
cell proven effect kill target human want see
proof select ablat effect safeti front
investor believ signific cell expans broad kill b-cell like
underli signific crs/neurotox concern
mechan safeti well understood could caus caar
given investor seek valid kill cell caar
therapi offer clean safeti profil
take given cart clinic trial current on-going believ
concept engin cell targeting/kil cell well establish
believ make select manag taken
technolog next level allow potenti circumv induct
find technolog promis await first clinic data
draw conclus translat preclin data
primer cart major limit
prior effect kill cancer cell immun system specif cytotox
cell must first identifi danger cancer cell identifi
cell activ prolifer effect elimin target/canc cell chimer
antigen receptor cell therapi build upon natur abil human
immun system recogn kill cancer cell genet engin cell
surfac receptor built equip patient cell abil recogn
bind antigen cell surfac protein found cancer cell cell therapi
involv genet transfer gene directli patient cell
collect leukapheresi ultim infus back patient
enabl cell effect recogn elimin cancer cell refer
design cart cell
extracellular part compris extracellular domain design robustli
bind tumor antigen fuse signal domain exhibit extracellular
domain compos fragment tumor-specif monoclon antibodi single-
chain variabl fragment scfv scfv typic direct cell surfac
protein express surfac vast major b-cell
malign well normal cell note express beyond b-cell
scarc activ extracellular domain bind tumor antigen
result activ cell cytotox respons cancer cell destruct
intracellular part intracellular part compris signal
portion receptor activ tumor antigen bind scfv
trigger cell activ prolifer cytokin secret elimin tumor cell
exhibit structur extracellular tumor-antigen recognit domain scfv consist
ofa fragment monoclon antibodi specif desir target intracellular signal
domain consist co-stimulatori domain bind tumor target antigen result
cell activ prolifer target cell elimin
design mirror two signal requir endogen cell activ
signal provid intracellular signal portion cell receptor tcr
signal provid co-stimulatori domain consist
extern antibodi portion anchor membran
linker transmembran sequenc optim tumor antigen bind
signal design equip molecul high specif
monoclon antibodi also cytotox memori capabl endogen
cell therapi characterist
date two cartcel product target approv us eu
yescarta market gilead kymriah market novarti therapi
approv relapsed/refractori diffus larg bcell lymphoma dlbcl otherwis
specifi highgrad bcell lymphoma dlbcl aris follicular lymphoma
addit yescarta approv relapsed/refractori primari mediastin bcell
lymphoma pmbcl anoth cart cell product current
evalu pivot clinic trial current product evalu
clinic trial mani target antigen underscor high potenti
cell therapi demonstr robust durabl respons test
indic indic approach engin cell kill cell highli
effect orr result exhibit hand robust efficaci cell
product coupl sever sometim fatal advers event major
follow ae rate exhibit
cytokin releas syndrom system inflammatori respons
induc releas cytokin cell follow activ upon
tumor recognit vivo cell like also activ bystand immun
cell macrophag turn also gener inflammatori cytokin
contribut pathophysiolog typic manifest
constitut symptom fever myalgia rigor fatigu loss appetit
lead multiorgan dysfunct death sever case symptom
grade shown exhibit manag appropri complet
revers degre cart cell expans cytokin level
correl sever interestingli patient exhibit
less like benefit therapi patient develop
occur parallel usual appear toxic encephalopathi
wordfind difficulti aphasia confus sever case lead
depress level conscious coma seizur motor weak cerebr
edema symptom grade shown exhibit pathophysiolog ican
less well understood similarli level cell expans
cytokin correl sever neurotox
immunodefici due cell aplasia on-target off-tumor toxic normal
cell well b-cell precursor express therefor
recognized/target kill cart cell b-cell aplasia expect
consequ success cell therapi durat
vari month year
importantli note preclin murin model therapi develop
human clinic use fail predict observ clinic toxic
exhibit major outcom key clinic trial first cart therapi
grade
neurotox grade
grade cytopenia on-going day
neelapu sattva manag toxic t-cell therapi hematolog oncolog
exhibit grade cytokin releas syndrom immun effector cellassoci
fever temperatur hypotens
fever hypotens requir vasopressor
fever hypotens requir one vasopressor
without vasopressin and/or hypoxia
nonrebreath mask venturi mask
score and/or depress level conscious awaken
seizur motor weak rais icp/cerebr edema
score and/or depress level conscious
awaken voic
seizur motor weak rais icp/cerebr edema
score and/or depress level conscious awaken
clinic seizur focal gener resolv rapidli
nonconvuls seizur eeg resolv intervent
focal/loc edema neuroimag
fever hypotens requir multipl
bipap intub mechan ventil
score patient unarous requir vigor repetit
tactil stimuli arous stupor coma
life-threaten prolong seizur min repetit clinic
electr seizur without return baselin
deep focal motor weak hemiparesi paraparesi
diffus cerebr edema neuroimag decerebr decort
postur cranial nerv vi palsi papilledema cush triad
neelapu sattva manag toxic t-cell therapi hematolog oncolog
design differ
chimer autoantibodi receptor cell platform leverag scientif
framework facilit target cell ablat autoimmun diseas
may potenti allow complet durabl remiss diseas
driven pathogen cell spare cell popul use
provid immun infect major characterist drive differ
caar extracellular target domain
exhibit design characterist cart left caart right therapi
antibodi fragment recogn antigen found surfac
leukemia cell well healthi cell unlik cell recogn
target cell extracellular domain featur antigen
select recogn pathogen solubl antibodi well limit
popul pathogen cell usual normal popul produc
antibodi key differ account pathogenic-onli cell ablat
therapi contrast therapi lead pan-b cell ablat
overal key potenti advantag cell therapi confer
includ follow
lower patient burden cost due potenti one-tim treatment
unlik current therapi cell-medi autoimmun diseas usual
requir chronic administr exampl see insid rituximab current
soc pv therapi design singl infus lead
complet durabl remiss cell-medi autoimmun diseas like
product memori cell significantli reduc burden
patient improv commerci viabil due one-tim payment exist
improv safeti preserv humor immun system unlik
current therapi cell-medi diseas target
cell cell high specif pathogen self-react cell
normal cell therebi spare humor immun system
render patient less suscept fatal infect observ
chronic immunosuppress also circumv need chronic in-
hospit treatment intraven immunoglobulin prophylact
improv efficaci complet durabl elimin pathogen cell
current standard care cell-medi autoimmun diseas offer
transient therapeut benefit coupl suppress humor immun
system therapeut activ cur potenti cell
analog cell cell cancer offer complet
durabl elimin root caus target autoimmun diseas given
efficaci sometim limit antigen escap could like
occur autoimmun diseas potenti deliv even
robust univers efficaci cell
pemphigu vulgari pv ideal initi indic
test differenti therapi
primer pemphigu
pemphigu belong categori autoimmun disord involv loss
keratinocyt adhes acantholysi lead intraepitheli blister eros
skin mucou membran preval form pemphigu
pemphigu vulgari pv pemphigu foliaceu pf refer
pv chronic life threaten diseas approv disease-modifi
treatment involv mucos tissu result variou symptom includ
limit dysphagia caus weight loss noseble hoars hydro
electrolyt imbal increas risk local system diseas
eventu lead higher mortal conjunct physic symptom pv also
impact patient qualiti life due high psychosoci impact refer
pv pathogen cell produc autoantibodi target desmoglein
therebi damag desmosom special structur enabl keratinocyt
adhes result format vesicl blister tradit serum
level autoantibodi directli correl sever diseas
type pv exist mucos pv impact mostli mucosa character
antibodi mainli target desmoglein constitut
depend cell adhes molecul belong cadherin famili
mucocutan pv character antibodi target desmoglein
lead loss cell-to-cel adhes skin mucou
mucos pv cabaletta lead program
manag select mucos pv lead indic evalu
technolog human main reason behind select mucos pv lead
indic includ follow
target establish antibodi serum featur sensit
specif therefor high sensitivity/specif render easy-to-
engag target without risk off-target engag
target well character cell key fragment well
character allow robust design
biolog clear antibodi elimin cell ablat rituximab improv
clinic outcom pv link pv patholog
preclin data support preclin data mice demonstr proof-of-
concept valid suggest efficaci without toxic human
cabaletta plan manufactur
manufactur process cart consequ caart entail five major step
apheresi cell select cell activ cell expans bead
remov note manufactur run correspond one patient time
last approxim week given complex cart manufactur process
mani challeng involv includ limit abil maintain
close steril process avail raw materi impact cell
viability/funct abil autom cost scalabl regulatori
uncertainti technolog transfer process optim regard
technolog transfer challeng observ invent relat cart
technolog commonli origin academ research center may
inexperienc current manufactur practic cgmp requir
process may sub-optimal littl support document raw
technolog origin invent univers sylvania
manag need transfer technolog cabaletta although
technolog transfer one major challeng involv cart
manufactur expect transit seamless follow reason
three cabaletta co-found affili experienc
field heavili involv discoveri
technolog cabaletta evp scienc technolog prior experi
transfer clinic program extern compani
involv cell therapi origin robust program extens
manufactur effort lead good document robust process
atyp academ environ
manag plan manufactur involv stage
manufactur cell vector materi requir support phi trial
mucos pv perform children hospit
philadelphia chop recal manufactur phi trial
fda-approv therapi kymriah also perform
manag alreadi implement agreement clinic
vector valid suffici vector secur year
follow initi manufactur chop support phi
studi manag transit manufactur
manag plan secur manufactur contract experienc
partner earli possibl allow suffici time vitro compar
product clinic valid next clinic studi note
manag plan musk-caart phi studi materi
manufactur although maintain option implement
overal manag expect cabaletta manufactur abil
independ
ultim manag build manufactur facil enough
capabl commerci scale product manag guid
facil design engin
note manag transit manufactur process
manag requir demonstr compar overal
process/product may last month final
note manag plan optim manufactur process consequ
decreas manufactur cost implement autom decreas gene transfer
ip protect cabaletta
cabaletta in-licens ip exchang receiv low singl
digit royalti us one patent alreadi issu addit
patent pend outsid us manag submit patent applic
pend exhibit detail differ patent indic importantli
current ip provid cabaletta ip potenti block other field
technolog specif cabaletta patent claim follow genet
modifi cell compris chimer autoantibodi receptor compris
extracellular domain compris fragment thereof bind
autoantibodi express b-cell transmembran domain intracellular
signal domain wherein cell express bind autoantibodi
express cell induc kill cell express autoantibodi link
exhibit issu pend patent cabaletta consid patent term extens
patent own exclus licens cabaletta field licens
patent co-own chop exclus licens cabaletta field
relat patent expir date
pend patent canada china eu
pend patent applic australia canada china eu japan korea mexico new
debat succeed clinic develop
overview preclin efficaci caar cell establish
murin model pv wherein cell select effect inhibit
growth hybridoma diminish serum autoantibodi titer
prevent blister format safeti front cell demonstr
absenc off-target toxic interact human membran
neighbor human cell vitro neither kill keratinocyt infiltr
skin mice vivo
street take investor see preclin data promis particularli
efficaci data larg demonstr equival suggest
clinic efficaci howev investor uneasi ambigu around
follow translat human neutral solubl antibodi
escap pathogen cell induct
neurotox investor focus phi acut safeti data
initi assess whether profil could replac rituximab
take think preclin data speak high potenti
succeed clinic develop acknowledg without clinic data
preclin model modestli derisk given past experi cell
therapi product believ safeti data acut efficaci measur
autoantibodi within month treatment major catalyst half-lif
week would expect see efficaci signal month
preclin efficaci
primer biolog design
pv caus pathogen autoreact cell express b-cell receptor bcr
immunoglobulin target transmembran glycoprotein compon
desmosom cell-cel junction keratinocyt destruct
antibodi pv disrupt adhes keratinocyt lead skin blister
exhibit featur extracellular cadherin ec domain
exhibit residu particularli import cell
adhes autoantibodi domain found
respect sera pv patient demonstr contribut
high frequenc domain pv importantli serum identifi
target sole and/or domain highlight and/or domain
much catalyt role pv domain
surfac includ first four epitop
therebi exclud follow reason pathogen
shorter conform fragment vs demonstr
improv efficaci preclin given cell activ depend
dimens peptide-mhc ligand refer
antigen link chain facilit
intracellular signal cytolyt activ cell exhibit
bcr surfac pathogen cell recogn four cadherin domain
epitop surfac cell cell engag
pathogen cell upon engag synaps gener cell
cell lead cytokin product b-cell kill lysi
exhibit schemat engag autoreact
 cell mucos pv
exhibit schemat nativ caar lentivir vector
use express
gali ann like angler fish caar lure prey molecular therapi
ellebrecht christoph et al re-engineering chimer antigen receptor cell target therapi
vitro demonstr dsg-caart target engag lysi
initi dr payn cabaletta founder team evalu whether
caart success engag kill cell vitro
implement two approach employ hybridoma cell multipli indefinit
produc antibodi target use
cell express pathogen igg clone
pv patient result two approach detail
approach establish exhibit among three design featur
differ epitop design found collect
deliv highest cytolysi kill antibodi
major case exhibit upper panel note design
compris epitop actual shown deliv minim cytolysi
like due increas length construct would enabl limit cell
activ refer expect outcom cytolysi exhibit upper
panel par result cell activ reflect inf product
exhibit lower panel given cell activ preced kill cell caart
depict lower panel exhibit design activ
collect outperform design demonstr
highest product inf product present differ antibodi relat
pv taken togeth vitro data use hybridoma suggest
design deliv effect engag relev antibodi
approach similar data observ cell express
pathogen igg clone pv patient inf
product shown lower panel exhibit indic
design provid superior cell activ compar design
interestingli design also found achiev superior vitro cell
activ compar
collect two vitro approach demonstr design
promis design develop deliv highest cell
activ combin augment lysi
exhibit specif cytolysi top panel level activ reflect ifn product
bottom panel caart cell differ type epitop
modifi ellebrecht christoph et al re-engineering chimer antigen receptor cell target therapi autoimmun diseas
import note solubl antibodi may bind neutral cell
therebi block kill autoreact cell explor phenomenon
vitro dr payn team investig cell function presenc
solubl polyclon antibodi mimick antibodi environ
encount evalu pv patient cytolyt effici
cell evalu presenc polyclon hybridoma
well presenc polyclon pv serum exhibit left
illustr exhibit reduc lysi presenc polyclon mixtur
ak hybridoma hint potenti neutral solubl antibodi
depend elisa index specif lysi rang
rel lysi absenc igg interestingli underscor
design deliv higher lysi compar design lysi
level evalu presenc pv serum ig exhibit right
found cytolyt efficaci impact significantli presenc
solubl antibodi particularli rang lysi level
absenc igg note experi lysi effici
nearli ident
dr payn group interrog conclud impact
solubl antibodi efficaci multifactori process depend
affin solubl antibodi caart posit solubl antibodi
rel cell note case solubl antibodi augment
cell efficaci costimulatori signal thu turn presenc
solubl antibodi advantag efficaci given data exact
impact solubl antibodi efficaci remain ambigu though
believ ultim impact efficaci significantli
exhibit lysi hour celltarget cell cocultur effector/target ratio
measur specif cytotox caar ts presenc solubl polyclon antibodi
indic elisa indic mean valu triplic cultur shown result
repres two independ experi cell two differ donor
ellebrecht christoph et al re-engineering chimer antigen receptor cell target therapi autoimmun diseas scienc
vivo demonstr dsg-caart efficaci mice
follow vitro demonstr design deliv superior
target engag kill among variou design dr payn group
sought explor cell function vivo pv mice model similarli
vitro experi two differ preclin model employ pv
hybridoma model human cell express bcr
clone pv patient result two approach discuss
pv hybridoma model hybridoma cell multipli indefinit produc
antibodi experi mice infus hybridoma produc antibodi
note mice bear polyclon serum
may constitut potenti sourc neutral thu model account
likelihood neutral solubl antibodi cell
infus mice hybridoma hinder growth hybridoma
importantli administr lead statist signific decreas
growth hybridoma compar control mice day exhibit addit
block growth hybridoma cell administr found
result statist signific decreas antibodi serum
mice day exhibit dampen serum conjunct inhibit
hybridoma growth led phenotyp improv treat mice exhibit
absenc blister unlik control mice exhibit taken togeth data
demonstr block antibodi improv pv
phenotyp mice addit underscor despit presenc solubl
antibodi cell abl deliv signific efficaci vivo
exhibit quantif hybridoma bioluminesc imag data replic
independ experi cell differ donor symbol repres one mous
wherea horizont black line repres mean group
ellebrecht christoph et al re-engineering chimer antigen receptor cell target therapi autoimmun diseas scienc
exhibit serum elisa day post-dos
quantifi iggproduct hybridoma cell
exhibit histolog mucos blister format
treatment none six caar ttreat mice versu five six control
ellebrecht christoph et al re-engineering chimer antigen receptor cell target therapi
ellebrecht christoph et al re-engineering chimer antigen receptor cell target therapi
 cell express bcr clone pv patient
model compris cell allow evalu efficaci
cart shown effect elimin cell human experi
bioluminesc imag implement quantifi number cell express
 cell receptor spleen bone marrow mice depict exhibit
elimin effici period
day unlik caar effect elimin cell
product treatment nontransduc cell elimin cell
express result product increasingli
progress period day
addit quantifi bioluminesc day qualit differ
bioluminesc level pathogen cell day day
investig illustr exhibit spleen bone marrow mice treat
cart clear pathogen cell unlik control mice ntd
wherein level autoreact cell high persist
supplementari indic efficaci similar cart
demonstr effect kill cell human
exhibit quantif cell express
igg caar nontransduc t-cell ntd treatment
quantif perform use bioluminesc imag
ellebrecht christoph et al re-engineering chimer antigen receptor cell target therapi autoimmun diseas scienc
exhibit bioluminesc day inject
ellebrecht christoph et al re-engineering chimer antigen receptor cell target therapi autoimmun diseas scienc
despit high efficaci cell escap also observ vivo
highlight day vivo experi cell mice escap kill
cell illustr fact serum antibodi level
mice similar antibodi level control mice exhibit red vs black data
point importantli also observ cell level spleen
mice whose cell escap kill similar mice escap
treatment demonstr escap treatment attribut lack
persist loss express
exhibit mice challeng treat control
cell allow progress day day serum antibodi
detect mice due escap
ellebrecht christoph et al re-engineering chimer antigen receptor cell target therapi autoimmun diseas scienc
interrog cell escap kill cell dr payn group
analyz level antibodi surfac find cell
escap kill cell surfac antibodi
surfac antibodi neg sigg- illustr red exhibit recal cell
without surfac antibodi contribut antibodi product
therefor believ involv pv pathogenesi taken
togeth data suggest cell escap cell may
relev diseas pathogenesi howev await clinic data phi
studi assess whether case human
exhibit cytometr analysi bone marrow treat mice left mice
bioluminesc signal day show signific gfp popul exist right
escap cell control caus gfp sigg- hybridoma cell
ellebrecht christoph et al re-engineering chimer antigen receptor cell target therapi autoimmun diseas scienc
preclin safeti
vitro demonstr safeti
explor off-target effect keratinocyt vitro dr
payn group assess bind keratinocyt
express desmocollin desmoglein shown exhibit
activ red color co-cultur keratinocyt contrast
present posit control wherebi exhibit strong activ
black color also confirm lysi experi exhibit wherein
cell found execut lysi human keratinocyt solid red
line posit control blue line exhibit robust lysi keratinocyt
addit experi manag test panel
human membran protein interact
human membran protein identifi hint limit off-target toxic caar
human final manag observ cytotox interact
caart cell primari human fcr-express cell suggest low
likelihood cytotox driven cell interact neighbor cell
exhibit caar-medi signal transduct data replic
least experi keratinocyt differ donor
exhibit cytotox caar ts control human
keratinocyt data repres mean valu triplic cultur
ellebrecht christoph et al re-engineering chimer antigen receptor cell target therapi
ellebrecht christoph et al re-engineering chimer antigen receptor cell target therapi
vivo demonstr safeti
autoantibodi caus upper layer epidermi separ base
result characterist eros blister assess safeti vivo
foreskin human graft mice variou type cell
cart inject intraven xenograft mice epidermal/derm
cell inflitr quantifi exhibit illustr phenotyp mice receiv
posit control character blister wherea mice receiv either
kill keratinocyt allow improv phenotyp without
blister given cell known pose risk skin caus
blister fact cell demonstr analog behavior
mice indic absenc off-target impact keratinocyt
quantif exhibit phenotyp present exhibit unlik
posit control mice wherebi level similar epidermi dermi hint
cell inflitr dermi epidermi mice treat show
limit infiltr cell epidermi
taken togeth data show deliv favor safeti profil
mice human skin xenograft await applic clinic trial
assess translat data human
exhibit microscop analysi human skin xenograft evalu
epiderm infiltr ts posit control ts
neg control inset dyskeratot keratinocyt
surround cell dash line show dermal-epiderm junction
exhibit quantif cell infiltr epidermi
dermi human skin xenograft symbol repres one mous
ellebrecht christoph et al re-engineering chimer antigen receptor cell target therapi
ellebrecht christoph et al re-engineering chimer antigen receptor cell target therapi
likelihood off-target appear low neurotox
establish common ae relat cell therapi
detail see insid primer cart major limit detail analysi
characterist patient exhibit sever suggest sever
associ higher diseas burden expand tumor/numb cancer cell
infus cell therapi refer exhibit illustr
percent blast cell bone marrow baselin diseas burden patient
suffer sever follow treatment significantli higher
compar patient exhibit sever
exhibit sever accord baselin diseas burden bone marrow
chemotherapi infus solid circl indic complet remiss open circl
respons horizont line median
maud shannon et al antigen receptor cell sustain remiss leukemia new england journal medicin
recal unlik cell indistinguish target entir cell
popul cancer patient cell design target kill small
portion typic cell popul given activ level
/car cell directli correl level target cell
expect undergo significantli lower activ compar cell
provid activ level driver cell therapi would
expect caus sever
await acut safeti data assess whether cell
clinic develop
manag initi phi open-label trial patient
relapsed/refractori mucos pv phi trial test rang
dose lowest dose equal dose minim
efficaci primari endpoint phi trial safeti toler
dose limit toxic measur ican neurotox toxic
relat therapi detail crs/ican grade see insid primer cart
major limit secondari object phi trial includ elisa
titer chang rate remiss time remiss durat remiss manufactur
success rate cell expans persist overal goal trial
identifi dose regimen deliv target engag coupl
given relat therapi specif ican
neurotox manag taken sever measur mitig potenti safeti risk
relat applic human addit safeti risk
discuss solubl antibodi escap cell may pose risk efficaci
profil overal manag allevi safety/efficaci risk follow
measur mitig efficaci risk
address caart neutral solubl antibodi pretreat patient
plasmapheresi ivig
address limit efficaci caart engraft increas dose and/or
preconditioning/lymphodeplet address potenti limit efficaci caart
engraft note manag first includ precondit
chemotherapi unlik administr clinic protocol
measur mitig safeti risk
minim risk crs/neurotox avoid lymphodeplet implement low
initi dose well dose fraction crs/neurotox case aris control
standard protocol depend acut
avoid toxic driven solubl antibodi employ conserv dose escal
conjunct fraction
address diseas flare skin toxic cross-react employ tropic steroid
plasmapheresi
exclud patient autoimmun disord requir immunosuppress
address emerg autoimmun diseas relaps pv use steroid
plasmapheresi immunosuppress
throughout phi clinic trial manag announc data
post-infus acut safeti data expect
post-infus antibodi titer measur elisa clinic
diseas activ chang mucos lesion respons absenc recurr may
observ month use steroid/immunosuppres treatment
expect
rituximab current soc pv
rituximab monoclon antibodi target antigen calcium
channel cell membran express cell therebi kill cell
indiscrimin rituximab engag cell caus direct induct
apoptosi complement-depend cytotox antibody-depend cellular
cytotox rituximab first drug ever approv fda
treatment moder sever pv
rituximab indic patient remain depend mg
prednisolon combin immunosuppress adjuv dose rituximab
usual either mg iv biweekli mg/m weekli dosag
administ repeatedli case diseas relaps meta-analysi treatment
rituximab sever pemphigu show remiss approxim total
patient howev incid seriou infect mortal rate
rel high rituximab elimin need steroid
immunosuppress agent patient publish studi use therapi
along rituximab refer
recent studi demonstr rituximab effect elimin
antibodi exhibit meta-analysi relev studi includ total
pv patient refer conclud major patient respond
rituximab howev relaps diseas month infus expect
addit cours administ analysi also highlight
follow relationship use rituximab refer
extrem seriou import infect septicemia pneumocysti carinii
pyelonephr hemolyt anemia lung abscess
infect brain abscess toxic epiderm necrolysi
exhibit anti-desmoglein left anti-desmoglein right antibodi elisa valu time
red line correspond patient treat standard corticosteroid regimen wherea blue
line correspond patient treat rituximab dash line repres cut-off valu
propos manufactur anti-desmoglein antibodi
joli pascal maud maho-vail prost-squarcioni first line use rituximab versu standard corticosteroid regimen treatment
patient pemphigu multicent random studi lancet
despit favor efficaci rituximab use requir chronic administr
weaken humor immun system indiscrimin kill cell caar
could overcom limit requir one-tim infus
circumv need chronic administr select target
pathogen cell spare healthi cell leav immun system intact
therefor cell therapi proven deliv clinic efficaci similar
rituximab accept safeti profil ultim becom soc pv
safeti data provid preliminari clariti
whether safeti profil could support replac rituximab
treatment pv
model sale us exhibit eu exhibit overal estim
peak risk-adjust sale us eu
model assumpt includ follow
mucos pv preval assum equal us eu
us base case assum approv wherea bull
case assum approv eu base case assum approv
wherea bull case assum approv
us eu probabl success assum equal
us annual price assum equal slightli
less doubl initi price therapi well total cost
administr given manag eu
consid annual price
us assum initi penetr grow gradual
eu assum initi penetr grow progress
exhibit market model mucos pv us
exhibit market model mucos pv eu
debat els cabaletta pipelin beyond mucos pv
valu
overview addit mucos pv cabaletta also
develop caart mucocutan pv muscle-specif kinas musk
myasthenia gravi hemophilia fviii allloantibodi manag
also identifi autoimmun diseas could efficaci
advanc program behind musk-caar vivo
data initi ind-en studi expect
street take investor appreci fact potenti broad
applic autoimmun diseas focus
importantli given overlap
mani investor believ success outcom former like yield
success latter program overal investor pipelin success gate
success mucos pv
take agre investor overlap mechanist driver
diseas mucos mucocutan pv high therefor
favor result mucos pv would probabl hint success outcom
mucocutan pv also highli interest musk mg none
current treatment efficaci await initi data pv major driver
mucocutan pv sever common subtyp pv impact
pv patient affect mucos pv although mucocutan pv caus
autoantibodi mucocutan pv patient autoantibodi
lead skin eros blister treatment paradigm
mucocutan pv similar mucos pv mainli involv immunosuppress
cabaletta develop therapi treatment
mucocutan pv design target and/or
autoantibodi pathogen cell caus mucocutan pv similar
exhibit consist five ec domain found sera
mucocutan pv patient probabl respect
previous found pathogen epitop take place first four domain
domain sera found react five ec domain
identifi ideal candid mucocutan pv manag evalu
variou combin domain primari human cell build upon prior
knowledg design addit evalu variou design
differ epitop manag also evalu efficacy/safeti
administ monotherapi combin
vitro demonstr efficaci mucocutan pv
manag test cytotox found induc
lysi slightli lower effici compar exhibit
interestingli manag observ
ad togeth ratio cell exhibit cytotox capabl neither
synergist antagonist manag current seek optim way
combin treatment mucocutan pv
exhibit schemat nativ top
exhibit cytotox level differ design cart
pathogen mab
vivo demonstr safeti mucocutan pv
potenti toxic cell skin evalu
use human skin xenograft compar posit anti-dsg neg
cart control cart util neg control given known human
clinic trial caus direct skin toxic shown exhibit exhibit
unlik anti-dsg posit control design
caus skin toxic similar cart data indic
caus off-target toxic
exhibit microscop analysi human skin xenograft evalu
epiderm infiltr caar ts posit control anti-dsg
exhibit quantif cell infiltr epidermi
dermi human skin xenograft symbol repres one
consider clinic develop
manag expect first clinic trial mucos pv inform
design protocol subsequ clinic trial mucocutan pv
note phi trial mucos pv also indic
safeti concern offer preliminari understand therapi
given larger popul mucocutan compar mucos pv fact
usual pv patient treat specialist manag expect
mucocutan pv trial enrol faster mucos pv manag also plan
use center mucos mucocutan pv
key decis remain made whether manag util
singl integr therapi dual bind domain separ
mix togeth former case size design
larger requir implement addit technolog ensur
size impact effici engin cell hand use
two therapi separ treatment make optim treatment
regimen challeng overal manag first assess clinic data
program advanc program clinic
model sale us exhibit eu exhibit overal
estim peak risk-adjust sale us eu
model assumpt includ follow
mucocutan pv preval assum equal us
us base case assum approv wherea bull
case assum approv eu base case assum approv
wherea bull case assum approv
us eu probabl success assum equal
us annual price assum equal
assumpt alon
us assum initi penetr grow gradual
eu assum initi penetr grow progress
exhibit market model mucocutan pv us
exhibit market model mucocutan pv eu
myasthenia gravi mg chronic autoimmun neuromuscular disord driven
autoantibodi target neuromuscular junction result weak skelet
muscl involv breath move includ arm leg muscl
control eye eyelid movement facial express chew talk swallow
may also affect current mg manag approach includ thymectomi
rebal immun system anticholinesteras medic increas muscl
growth immunosuppress plasmapheresi intraven immunoglobulin
remov auto-antibodi temporarili refer
major mg patient antibodi target
acetylcholin receptor achr wherea patient found bear
antibodi muscle- specif tyrosin kinas musk receptor typic
patient suffer musk mg achr antibodi refer
musk mg patient usual follow differ treatment paradigm mg patient
respons treatment distinct recommend musk mg treatment
approach includ corticosteroid prednison usual combin steroid-
spare agent azathioprin patient respons cyclophosphamid
use acut exacerb treat plasma exchang shown
superior ivig ivig also use final role thymectomi mmg
antibodi musk mg similar size structur base clinic
studi unlik pv pathogen autoantibodi musk mg antibodi may target
epitop found extracellular domain musk
manag creat name musk-t potenti musk mg
therapi includ four extracellular domain fz engin
construct current test vitro/vivo experi
preliminari vitro experi shown exhibit manag
demonstr musk-caart success engag target achiev lysi
exhibit note manag initi develop two version musk-
wild type musk wt exhibit modifi version muskmut
exhibit due concern wild type version may caus toxic driven
interact molecul howev manag address toxic
concern advanc wild type version importantli lysi level
achiev wt musk-caart cell similar cart given cart
shown deliv clinic efficaci human data indic
promis potenti musk-caar deliv effici pathogen cell kill musk
exhibit efficaci level three condit target wt cell neg
manag present vivo data mice activ toler
musk-caart musk note manag plan advanc
musk-caart program clinic prior advanc
program await initi data program prior advanc
model musk-caart sale us exhibit eu exhibit overal
estim peak risk-adjust sale us eu
model assumpt includ follow
musk mg preval assum equal us eu
us base case assum musk-caart approv wherea bull
case assum approv eu base case assum approv
wherea bull case assum approv
us eu musk-caart probabl success assum equal
us annual price musk-caart assum equal eu
consid musk-caart annual price price higher pv given
signific cost save could associ elimin current soc
regiment cost
us assum initi penetr grow gradual
eu assum initi penetr grow progress
exhibit musk-caart market model musk mg us
exhibit musk-caart market model musk mg eu
hemophilia inherit bleed disord character impair blood
clot hemophilia patient tend bleed healthi injuri surgeri
dental procedur disord sever moder mild hemophilia
caus mutat gene lead low level protein factor viii
necessari blood clot format refer
soc includ medic factor viii replac therapi immun system
patient sever form hemophilia may gener antibodi hinder
replac factor viii function although consid cell
mediat autoimmun diseas manag plan develop caart therapi
hemophilia patient develop antibodi factor viii replac therapi
cabaletta fviii-caart aim kill cell produc fviii neutral
antibodi therefor make hemophilia patient elig replac therapi
popul target fviii-caart includ hemophilia
patient sever diseas symptom total patient us note
hemophilia patient fviii alloantibodi higher mortal
therefor need new treatment
fviii consist six domain shown hemophilia
patient usual carri alloantibodi target domain
manag alreadi engin preliminari fviii-caar design target
fviii part optim design current on-going
larg size fviii-caart like requir manag implement advanc
technolog decreas size
note recent studi report design fviii-specif treg
target fviii domain demonstr strong inhibit t- b-cell
respons fviii vitro vivo refer
mani autoimmun indic could caart appli
major driver autoimmun diseas loss b-cell toler pathogen
gener autoantibodi date distinct autoimmun diseas
describ includ multipl sclerosi rheumatoid arthriti system lupu
erythematosu role cell autoimmun diseas includ variou cellular
function well-establish secret autoantibodi autoantigen
present ensu reciproc interact cell secret inflammatori
cytokin gener ectop germin center importantli implement
mechan cell involv autoimmun diseas
tradit view antibodi mediat also autoimmun diseas
commonli classifi cell mediat refer refer
given autoimmun diseas exist wherein cell poss key role believ
success technolog may potenti find broad applic
autoimmun diseas beyond three diseas current list cabaletta pipelin
exampl could also appli treat autoantibody-associ
neonat lupu syndrom refer howev think caar
technolog appli autoimmun indic autoantigen
indic meet follow criteria must interfer
physiolog function must well character
effici display cell given date autoantigen
identifi refer display autoantigen cell may
feasibl remain cautiou bandwidth applic
optimist howev ultim manag could also expand applic
cell mediat autoimmun diseas type diabet
neelapu sattva manag toxic t-cell therapi hematolog
seimetz dian karl heller jan richter approv first car-t
solv hurdl atmp cell medicin
ellebrecht christoph et al re-engineering chimer antigen receptor cell
target therapi autoimmun diseas scienc
gali ann like angler fish caar lure prey molecular therapi
chatenoud lucienn precis medicin autoimmun diseas natur
choudhuri kaushik et al t-cell receptor trigger critic depend
dimens peptide-mhc ligand natur
challeng bioprocess intern e-book seri
levin bruce et al global manufactur cell therapi molecular
maud shannon et al antigen receptor cell sustain remiss
leukemia new england journal medicin
el-salem khalid et al treatment musk-associ myasthenia gravi current
treatment option neurolog
cell suppress t-and b-cell respons fviii blood
hamp christian cell autoimmun diseas scientifica
tavakolpour soheil et al sixteen-year histori rituximab therapi
joli pascal maud maho-vail prost-squarcioni first line use
rituximab versu standard corticosteroid regimen treatment patient
gregori stamati et al manag pemphigu vulgari challeng
solut clinic cosmet investig dermatolog
amber kyle manuel valdebran sergei grando non-desmoglein
antibodi patient pemphigu vulgari frontier immunolog
spindler volker et al mechan caus loss keratinocyt cohes
pemphigu journal investig dermatolog
